key: cord-0756647-6ev8t9ux
authors: Khurana, Ananta; Sethia, Khushboo
title: Using Cyclosporine in the COVID era: an emergent need for caution
date: 2020-06-27
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.06.990
sha: 3ce6f06ad33e0ddd7dd13d16bdb5d7cc35b80a1f
doc_id: 756647
cord_uid: 6ev8t9ux

nan

Using Cyclosporine in the COVID era: an emergent need for caution 28 Dear Editor 29 We read the paper "Cyclosporine therapy during the COVID-19 pandemic is not a reason for 30 concern" by Rudnicka et al 1 and wish to highlight some flawed interpretations which can 31 encourage complacency in use of a drug where caution is needed. 

Cyclosporine therapy during the COVID-19 72 pandemic is not a reason for concern

Cyclosporin A inhibits the 74 replication of diverse coronaviruses

The SARS-Coronavirus-Host Interactome: 76 Identification of Cyclophilins as Target for Pan-Coronavirus Inhibitors

Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV 79 agents

Interferon-β and mycophenolic acid are potent 81 inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays

Thiopurine Analogue Inhibitors of Severe Acute 84

Respiratory Syndrome-Coronavirus Papain-Like Protease, a Deubiquitinating and 85 deISGylating Enzyme

Immunosuppressive agents for dermatological indications in the 87 ongoing COVID 19 pandemic: rationalizing use and clinical applicability

Infection and Cyclosporine